Pfizer Inc. $PFE Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its position in Pfizer Inc. (NYSE:PFE) by 1.8% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,398,061 shares of the biopharmaceutical company’s stock after selling 44,533 shares during the quarter. Handelsbanken Fonder AB’s holdings in Pfizer were worth $61,103,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer in the 2nd quarter valued at approximately $30,000. Darwin Wealth Management LLC acquired a new position in Pfizer during the 2nd quarter worth approximately $32,000. Evelyn Partners Asset Management Ltd purchased a new position in shares of Pfizer during the 2nd quarter worth approximately $33,000. Finally, True Wealth Design LLC lifted its holdings in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Bank of America dropped their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. UBS Group assumed coverage on shares of Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Royal Bank Of Canada assumed coverage on shares of Pfizer in a report on Tuesday. They set an “underperform” rating and a $25.00 price objective on the stock. Finally, Scotiabank started coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $27.70.

Pfizer Stock Up 0.1%

PFE stock opened at $27.11 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company’s 50 day simple moving average is $26.08 and its 200-day simple moving average is $25.39. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The firm has a market capitalization of $154.14 billion, a PE ratio of 19.93 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the firm posted $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants full approval to Pfizer’s BRAFTOVI regimen for metastatic colorectal cancer — expands label to first‑line use, supporting upside to oncology sales and the “bull case” narratives for PFE. Pfizer’s Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment
• Positive Sentiment: Analyses argue the BRAFTOVI approval could re‑shape Pfizer’s growth outlook in oncology, providing a clear revenue catalyst if uptake in first‑line mCRC is strong. The Bull Case For Pfizer (PFE) Could Change Following New First-Line BRAFTOVI Colorectal Cancer Approval
• Positive Sentiment: Pfizer secures rights to a new GLP‑1 candidate as the company broadens its obesity pipeline — a strategic move to chase a large market and diversify future revenue streams. Pfizer secures rights to new GLP-1 as obesity push gathers pace
• Neutral Sentiment: Dividend narrative remains supportive: articles highlighting Pfizer’s 6%+ yield and retiree flows into dividend funds underscore investor appetite for PFE income, which can stabilize the stock. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.
• Neutral Sentiment: Zacks upgraded Pfizer from “strong sell” to “hold,” a modest positive signal but not a bullish re‑rating; it may temper short‑term selling. Zacks.com
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of an “insurmountable” $15B–$20B revenue decline through 2030 — a bearish structural thesis that could cap valuation upside. RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study — a pipeline setback that reduces optionality in immunology and may modestly pressure sentiment. Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.